Life is Rare

November 18, 2026

JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Strengthens Community Ties Through Plant Tour at Kobe Science Park Center

Hyogo, Japan – November 18, 2026 – JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, welcomed local residents to its Kobe Science Park Center (KSPC) in Nishi-ku, Kobe, on November 14, 2026, for the company's third annual community plant tour, a program launched in 2024. The event offered an opportunity to learn about JCR's work in rare diseases and gain firsthand insight into how biopharmaceuticals are manufactured.

Thirty-eight residents participated in the event, which included an introduction to JCR's business, its efforts to develop treatments for rare diseases, and the quality control and production processes behind its medicines. Participants toured KSPC's operational active pharmaceutical ingredient (API) plant and learned about the new KSPC formulation plant, which is being readied for operation, highlighting JCR's efforts to strengthen its manufacturing capabilities.



Presentation on JCR's business activities and biopharmaceutical manufacturing



Participants viewing the new KSPC formulation plant from the terrace of the KSPC API plant

Throughout the visit, participants engaged in discussions with JCR representatives, asking questions about biopharmaceutical manufacturing processes and global-standard manufacturing operations. Feedback reflected particular interest in seeing production facilities not normally open to the public. Participants also expressed pride in learning that a company rooted in the local community is engaged in the development of innovative medicines for patients around the world living with rare and serious diseases.

JCR values its relationship with the local community and remains committed to fostering trust through open dialogue and continued engagement.

For more information about the new KSPC formulation plant, please visit:
https://jcrpharm.com/wp-content/uploads/2025/03/Notice-Concerning-the-Start-of-Construction-of-a-New-Drug-Product-Plant.pdf

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our

scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including partners, patients and employees. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit JCR's global website: https://jcrpharm.com/.

Contact:
Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jp.jcrpharm.com

###